Additional European C21 BioVentures Conference Exhibitor Profiles.LONDON -- European C21 BioVentures Conference takes place March 22 - 23 at the QEII Conference Centre in London, United Kingdom. For in-depth information about the event visit http://www.techvision.com/ec21/. Below are profiles from European C21 BioVentures Conference exhibitors; breaking news releases are available at http://www.tradeshownews.com, Business Wire's trade show, conference and event news resource. Business Wire is the official news wire service for European C21 BioVentures Conference. Company: Atugen AG Investor Relations Contact: Thomas Christely Web: www.atugen.com Date of Presentation: 22 March 2005 Time of Presentation: 03:15 pm - 03:30pm Company description: Atugen AG specializes in applying RNA interference RNA interference n. A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes. (RNAi) to develop a new class of drugs with vast pharmaceutical potential. The Company has core competence Core competence Primary area of expertise. Narrowly defined fields or tasks at which a company or business excels. Primary areas of specialty. in functional gene silencing and is a leader in developing short interfering RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic (siRNA) inhibitors. These structures are based on Atugen's atuRNAi(TM) technology, chemically stabilized siRNA molecules, which are delivered to target tissues via atuPLEX(TM), Atugen's proprietary liposomal system for in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. delivery of siRNA/atuRNAi(TM). Company: Intercell AG Ticker Symbol & Exchange: ICLL, VSE Investor Relations Contact: Katharina Wieser Investor Relations Contact Phone: +43.1.20620.222 Web: http://www.intercell.com Date of Presentation: March 23, 2005 Time of Presentation: 09:30 am Company description: Intercell AG is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prophylaxis and treatment of diseases with substantial unmet needs. The Company's unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP GMP (guanosine monophosphate): see guanine. facilities. Intercell's technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including Sanofi Aventis, Merck&Co., Inc., Scigen Ltd. and the Statens Serum Institut Statens Serum Institut (English: the State Serum Institute), or SSI for short, is a Danish sector research institute located on the island of Amager in Copenhagen. . The Company has a broad development pipeline with a vaccine for Japanese Encephalitis Japanese Encephalitis Definition Japanese encephalitis is an infection of the brain caused by a virus. The virus is transmitted to humans by mosquitoes. about to enter Phase III and a vaccine for Hepatitis C undergoing Phase II trials. Intercell is listed on the Vienna Stock Exchange Vienna Stock Exchange (VSX) One of the world's oldest exchanges, which accounts for approximately 50% of Austrian stock transactions; the balance are traded OTC. under the symbol "ICLL ICLL Index to Canadian Legal Literature ". Company: Xanthus Life Sciences, Inc. Investor Relations Contact: Lisa Terry Investor Relations Contact Phone: (617) 225-0522, ext. 105 Web: www.xanthus.com Date of Presentation: Tuesday, March 22, 2005 Time of Presentation: 2:30pm -Stream A - 4th Floor, Abbey Company description: Xanthus is an oncology drug development company that has assembled an outstanding development team with an impressive record of FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. filings and drug approvals. Xanthus has three small molecules advancing in clinical development for multiple cancer indications. Each of these product candidates was inlicensed based on significant clinical and/or preclinical data supporting safety and activity. Xanthus also has a proprietary technology to individualize patient dosing, which it believes may improve the therapeutic window of drugs. Xanthus believes that its individualized dosing technology may help improve the performance of certain drugs in development, and in the life cycle management of certain marketed products, without limiting patient populations or markets. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion